17.04

0.23% 0.12

Neuropace Inc (NPCE)

Panoramica Notizia Cronologia dei prezzi Financials Forum Previsione

Precedente Chiudi:

$16.92

Aprire:

$17

Volume 24 ore:

29,762

Relative Volume:

0.15

Capitalizzazione di mercato:

$580.62M

Reddito:

$99.99M

Utile/perdita netta:

$-21.47M

Rapporto P/E:

-25.83

EPS:

-0.6597

Flusso di cassa netto:

$-11.34M

1 W Prestazione:

+6.99%

1M Prestazione:

+0.94%

6M Prestazione:

+2.78%

1 anno Prestazione:

-4.08%

Intervallo 1D:

$16.75

$17.40

Intervallo di 1 settimana:

$15.62

$17.40

Portata 52W:

$7.5625

$19.60

Neuropace Inc Stock (NPCE) Company Profile

Nome

Neuropace Inc

Settore

Healthcare (1110)

Industria

Medical Devices (143)

Telefono

(650) 237-2700

Indirizzo

455 N. BERNARDO AVENUE, MOUNTAIN VIEW

Dipendente

220

Cinguettio

Prossima data di guadagno

2026-05-12

Ultimi documenti SEC

NPCE's Discussions on Twitter

Compare NPCE vs ABT, SYK, MDT, BSX, EW

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
NPCE Neuropace Inc	17.03	576.87M	99.99M	-21.47M	-11.34M	-0.6597
ABT Abbott Laboratories	86.53	152.25B	45.13B	6.28B	7.38B	3.5895
SYK Stryker Corp	312.00	121.33B	25.27B	3.34B	4.57B	8.6334
MDT Medtronic Plc	78.09	100.91B	35.48B	4.64B	5.41B	3.582
BSX Boston Scientific Corp	57.97	85.88B	20.62B	3.56B	3.48B	2.3847
EW Edwards Lifesciences Corp	87.12	49.39B	6.30B	1.07B	1.09B	1.8406

Neuropace Inc Stock (NPCE) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2025-05-28	Iniziato	H.C. Wainwright	Buy
2025-01-21	Iniziato	UBS	Buy
2024-03-14	Aggiornamento	Wells Fargo	Equal Weight → Overweight
2024-01-30	Iniziato	Leerink Partners	Outperform
2023-11-10	Iniziato	Cantor Fitzgerald	Overweight
2023-08-24	Aggiornamento	Morgan Stanley	Underweight → Equal-Weight
2023-02-22	Iniziato	Lake Street	Buy
2022-04-06	Iniziato	Wolfe Research	Outperform
2022-01-19	Downgrade	Wells Fargo	Overweight → Equal Weight
2022-01-07	Downgrade	Morgan Stanley	Equal-Weight → Underweight
2021-11-11	Downgrade	Morgan Stanley	Overweight → Equal-Weight
2021-08-18	Iniziato	Robert W. Baird	Outperform
2021-05-17	Iniziato	JP Morgan	Overweight
2021-05-17	Iniziato	Morgan Stanley	Overweight
2021-05-17	Iniziato	SVB Leerink	Outperform
2021-05-17	Iniziato	Wells Fargo	Overweight

Mostra tutto

Neuropace Inc Borsa (NPCE) Ultime notizie

May 25, 2026

NeuroPace (NPCE) CFO receives RSU and stock option awards in Form 4 filing - Stock Titan

May 19, 2026

NeuroPace (NPCE) CMO receives new RSU and stock option awards - Stock Titan

May 19, 2026

NeuroPace (NPCE) CEO receives new RSU and stock option awards - Stock Titan

May 19, 2026

May 18, 2026

Here's why you should add NeuroPace stock to your portfolio now - MSN

May 18, 2026

H.C. Wainwright raises NeuroPace stock price target to $20 on guidance - Investing.com Australia

May 18, 2026

May 15, 2026

NPCE Maintains by HC Wainwright & Co. -- Price Target Raised to $20 - GuruFocus

May 15, 2026

First Light, Mathew Arens report ~2.9M NPCE shares (NPCE) - Stock Titan

May 15, 2026

OrbiMed reports 2,096,527 shares (6.2%) in NeuroPace (NPCE) - Stock Titan

May 15, 2026

H.C. Wainwright Maintains NeuroPace(NPCE.US) With Buy Rating, Raises Target Price to $20 - Moomoo

May 15, 2026

Wells Fargo Maintains NeuroPace(NPCE.US) With Buy Rating, Maintains Target Price $19 - Moomoo

May 15, 2026

NeuroPace, Inc. (NASDAQ:NPCE) First-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year - simplywall.st

May 15, 2026

May 14, 2026

(NPCE) Movement as an Input in Quant Signal Sets - Stock Traders Daily

May 14, 2026

NeuroPace, Inc. (NASDAQ:NPCE) First-Quarter Results: Here's What Analysts Are Forecasting For This Year - Yahoo Finance

May 14, 2026